Aggressive Smoking Cessation Trial (ASAP) (NCT05257629)
Aggressive Smoking Cessation Therapy Among People at Elevated Cardiovascular Risk (ASAP) Trial
🩺 Plain-English Summary (8th-Grade Level)
The ASAP Trial is a 5-year, multi-centre, randomized controlled trial that will assess the efficacy, safety, and tolerability of aggressive smoking cessation therapy among people at elevated cardiovascular risk. It will recruit 798 adult patients smoking on average at least 10 conventional (tobacco) cigarettes per day who are motivated to quit smoking and have either been diagnosed with ACS requiring hospitalization or are outpatients at elevated cardiovascular risk. Patients will be randomized (1:1) to one of two treatment arms: (1) combination therapy of varenicline and nicotine e-cigarettes plus counseling or (2) varenicline plus counseling for 12 weeks, with 52-week follow-up.
Who can join: Review the eligibility criteria below.
Location: Fraser Clinical Trials — New Westminster, British Columbia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Fraser Clinical Trials — New Westminster, British Columbia
- Dr. Georges-L.-Dumont University Hospital Center — Moncton, New Brunswick
- NL Health Sciences — St. John's, Newfoundland and Labrador
- Queen Elizabeth II Health Sciences Center — Halifax, Nova Scotia
- St. Joseph's Hospital — London, Ontario
- University of Ottawa Heart Institute — Ottawa, Ontario
- Sunnybrook Health Sciences Centre — Toronto, Ontario
- Montreal Heart Institute — Montreal, Quebec
- Centre Hospitalier de L'Universite de Montreal — Montreal, Quebec
- Montreal General Hospital — Montreal, Quebec
- Jewish General Hospital — Montreal, Quebec
- Institut Universitaire de Cardiologie et de Pneumologie de Québec — Québec, Quebec
- Royal University Hospital — Saskatoon, Saskatchewan
📞 Contact the Study Coordinator
Phone: (514) 340-8222
Email: ASAP.Trial@ladydavis.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Coronary Syndrome
- LEADERS FREE II: BioFreedom™ Pivotal Study — Huntsville, Alabama
- OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study — Scottsdale, Arizona
- Post Acute Cardiac Event Smoking (PACES) Study — Minneapolis, Minnesota
- DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid — Montreal, Quebec
- Tailoring Post Discharge - Remote Education and Access for Cardiac Health — Winnipeg, Manitoba
- A Prospective Research Investigation of Ischemia Using MCG — Rochester, Minnesota
Explore by condition: All Acute Coronary Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.